• Explore /
  • Poster
  • / Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.

Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.

Abstract Video & Slides Poster

Authors

null

Sandra P. D'Angelo

Memorial Sloan Kettering Cancer Center, New York, NY

Sandra P. D'Angelo , Mihaela Druta , Brian Andrew Van Tine , David A. Liebner , Scott Schuetze , Aisha N. Hasan , Andrew P. Holmes , Anne Huff , Gurpreet Singh Kapoor , Stefan Zajic , Neeta Somaiah

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Sarcoma

Track

Sarcoma

Sub Track

Soft Tissue Tumors

Clinical Trial Registration Number

NCT02992743

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 11521)

DOI

10.1200/JCO.2021.39.15_suppl.11521

Abstract #

11521

Abstract Disclosures

Similar Posters

First Author: Sandra P. D'Angelo

Poster

2024 ASCO Annual Meeting

<span>Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.</span>

Phase IIA study of high-affinity TCR-T (TAEST16001) targeting NY-ESO-1 in soft tissue sarcoma.

First Author: Jiayong Liu

First Author: Sandra P. D'Angelo

First Author: Dejka M. Araujo